Table 3.
Xpert MTB/RIF Results and Concordance With MTBDRplus
| Xpert MTB/RIF | MTBDRplus, n (%) | Total | ||||||
|---|---|---|---|---|---|---|---|---|
| RIFR-INHR | RIFR-INHS | RIFS-INHS | RIFR-INHNv | RIFS-INHR | Non-MTB | Neg | ||
| MTB-pos/RIFR | 45 (61.6) | 22 (30.1) | 4 (5.5) | 2 (2.7) | 0 | 0 | 0 | 73 (100) |
| MTB-pos/RIFS | 0 | 0 | 79 (98.7) | 0 | 11 (1.3) | 0 | 0 | 90 (100) |
| MTB-Neg | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 5 (100) |
| MTB-pos/RIFInd | 0 | 0 | 0 | 0 | 0 | 3 (27.3) | 8 (72.7) | 11 (100) |
| Total | 45 (25.1) | 22 (12.3) | 83 (46.4) | 2 (1.1) | 11 (0.6) | 8 (10.1) | 8 (4.5) | 179 (100) |
Abbreviations: INHNv, not valid results for INH (there was not clear evidence that these specimens were INH resistant since the katG and inhA bands were extremely faint); INHR, isoniazid resistant; INHS, isoniazid susceptible; MTB, Mycobacterium tuberculosis; Neg, negative; pos, positive; RIF, rifampicin; RIFInd, rifampicin indeterminate; RIFR, rifampicin resistant; RIFS, rifampicin susceptible.